Page 3 Jasinski

maximum dose of \underline{d} -propoxyphene napsylate was chosen as molar equivalents to \underline{d} -propoxyphene hydrochloride (210 and 420 mg).

Drug effects were measured by change in pupil size (measured photographically⁸) and scores gn₁ scales from the Subjects' and Observers' Single Dose Opiate Questionnaire^{9,10} and items from the Morphine-Benzedrine Group (MBG) Scale.

Subcutaneous morphine and oral d-propoxyphene hydrochloride produced a dose-related miosis and morphine-like subjective effects. d-Propoxyphene was 1/30 to 1/40 as potent as morphine but d-propoxyphene hydrochloride, 600 mg orally, and morphine, 20 mg subcutaneously, produced equivalent effects (Fig. 1). These findings with the hydrochloride are similar to observations reported previously.




Figure 1. Dose response curves utilizing total 5 hour scores for the comparison of orally administered d-propoxyphene napsylate, orally administered d-propoxyphene hydrochloride and subcutaneously administered placebo. Potency estimates with 95% confidence limits in parentheses are expressed as mg of d-propoxyphene napsylate orally equivalent to 1 mg morphine sulfate subcutaneously (PH:M) and mg of d-propoxyphene napsylate orally equivalent to 1 mg d-propoxyphene hydrochloride orally (PN:PH).